Case Report: Recessive Dystrophic Epidermolysis Bullosa With Severe Esophageal Stenosis: A Case Report and Literature Review

Zhen Xu¹, Tianqiao Huang¹, Min Pan², Yichuan Huang¹ and Yan Jiang¹*

¹Department of Otolaryngology Head and Neck Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China, ²Department of Dermatology, The Affiliated Hospital of Qingdao University, Qingdao, China

Keywords: therapy, epidermolysis bullosa, recessive dystrophic epidermolysis bullosa, esophageal stenosis, dysphagia

INTRODUCTION

Epidermolysis bullosa (EB) is a rare genetic disease that has no effective management or cure. Patients with EB may manifest with skin and mucous membrane fragility, blisters, erosions and scars. Based on the 2014 diagnosis and treatment guidelines, EB can be divided into four types: EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB), and Kindler syndrome (1). DEB usually affects the skin and nails at birth, which can be divided into two subtypes, namely the dominant dystrophic epidermolysis bullosa (DDEB) and recessive dystrophic epidermolysis bullosa (RDEB) (2). Furthermore, based on different clinical features, RDEB has been classified into severe Hallopeau-Siemens type (RDEB-HS) or the milder form called RDEB-nHS. Patients with RDEB-HS have systemic lesions and scars on hands and feet, leading to finger fusion and severe mucosal involvement, while those with RDEB-nHS may have local or systemic mild dermatological manifestations, mostly without finger fusion and without the involvement of the extradermal organs (3). Here, we report the case of a male patient with severe esophageal stricture due to recessive dystrophic EB. Currently, there is no effective treatment for EB complicated with severe esophageal stricture, although esophageal dilation and gastrostomy may be attempted.

CLINICAL CASE PRESENTATION

A 28-year-old male was admitted to the Department of Otorhinolaryngology, Head and Neck Surgery of the Affiliated Hospital of Qingdao University, China, with a week history of progressively severe dysphagia to a liquid diet, hemoptysis, and sore throat for 1 week. Previously, he was diagnosed with COL7A1:DEB, Bart-type non-specific epidermolysis bullosa through genetic testing. He started experiencing irregular and intermittent hemoptysis with no hematemesis after swallowing pieces of shrimp skin 2 years ago, followed by a gradual onset of dysphagia. Since then, he had attended several hospitals for esophageal dilation or esophageal stent insertion, which had not been clinically successful due to the uncertainty of the therapeutic effect caused by congenital disease.

On physical examination, the patient weighed 53 kg, 170 cm in height, with a BMI of 18.34. Incomplete and deformed nails on hands and feet were observed (Figure 1). Based on the Atkinson score (4), the patient’s dysphagia was grade IV (Grade 0: No dysphagia and able to eat normally; Grade I: Occasional dysphagia but able to eat some solid food; Grade II: able to consume a semi-fluid diet; Grade III: able to consume liquid diet only; grade IV: complete dysphagia). The nutritional assessment revealed that the patient had a low body mass index with moderate malnutrition. He was
investigated with a barium swallow test (Figure 2) and electronic laryngoscopy (Figure 3), which demonstrated a severely narrowed hypopharynx-esophageal entrance. The strictured esophagus could not be traversed even with an ultra-fine gastroscopy. Biopsies were taken from the strictured esophagus, which showed squamous epithelial
shedding and proliferation of submucosal granulation tissue (Figure 4).

According to the patient’s previous genetic sequencing (supplied by the Beijing Kangso Medical Inspection), he had COL7A1:DEB, Bart-type non-specific epidermolysis bullosa (detection gene: COL7A1 [type VII collagen gene], position: chr3:48606879, variation: c.7012C>T and c.7615G>T, variation type: heterozygous), which belongs to an extremely rare autosomal recessive genetic dystrophy type of epidermolysis bullosa (RDEB). Further genetic testing on the patient’s immediate family members (father, mother, and elder brother) revealed that the patient carried two heterozygous mutation vectors, with c.7012C>T derived from his father’s heterozygous gene. c.7012C>T (nucleotide 7012 in the coding region is changed from C to T) represents the heterozygous nucleotide mutation, which causes the codon containing nucleotide 2338, coding for arginine, to be read as a stop codon (p.Arg2338Ter), leading to premature termination of the peptide chain synthesis, which is thus a nonsense mutation. c.7615G>T was derived from his mother’s heterozygous gene, while the gene type of the patient’s brother at this locus was similar to that of the mother. c.7615G>T (nucleotide 7615 in the coding region is changed from G to T) represents the heterozygous nucleotide mutation, which causes the amino acid 2539 to change from glycine to cysteine (p.Gly2539Cys), and is recognized as a missense mutation. Mutations in the COL7A1 gene can lead to the abnormal synthesis of type VII collagen. We postulated that in our patient, the c.7012C>T and c.7615G>T gene mutations might have affected the protein function.

**DISCUSSION**

Dystrophic epidermolysis bullosa can be inherited in an autosomal dominant or recessive pattern. Patients with DEB may present with recurrent skin blisters, ulcers, atrophic scars, miliary rash, mucosal lesions, or white papules. Micro-dense horizontal tissue separation under the basement membrane, skin blisters that develop at birth or in infancy decrease in frequency with age, and family variation (5). Following a mild mechanical injury, blisters, erosions and scars of the skin and mucous membranes are formed. In the pathogenic gene COL7A1, c.7012C>T is derived from a heterozygous mutation of the father, while c.7615G>T is derived from a heterozygous mutation of the mother. After searching online databases (http://www.col7a1-database.info), It was found that the pathogenicity of the variant c.7012C>T associated with epidermolysis bullosa had been previously reported. However, the variant c.7615G>T, which is extremely rare clinically, has not been linked to the disease. In our patient, a detailed inquiry in the medical history revealed that the patient had gingival mucosal blisters since birth, which was apparent with ruptures during feeding. Repeated episodes of these had continued during infancy and toddler age, which eventually resolved at adulthood. However, nail dystrophy such as abnormal nail shape and slow growth had persisted. Furthermore, recurring blistering and ulceration of the esophageal mucosa due to frictions with swallowed objects had eventually led to the occurrence of esophageal stenosis. Although the incidence of esophageal stenosis in patients with DEB is more than 50%, reports of patients with severe stenosis are rather limited in the literature (6). To date, there is no effective treatment for epidermolysis bullosa. In general, skin care affects the prognosis and quality of life of patients (6). Nevertheless, several studies have suggested the use of drugs to improve skin conditions in patients with EB. For instance, losartan (7) may relieve skin blisters, raloxifene reduces fibrosis of the skin and mucous membrane, while N-acetylcysteine reduces skin inflammation (8). Bornert et al. have shown that QR-313 (an antisense oligonucleotide) regulates the splicing of exon 73 of type VII collagen, thus restoring the abundance of collagen VII in the skin of RDEB patients and improving the quality of wound healing by influencing the fibrosis of the wound, thereby reducing the formation of wound scars and recurring skin damage (9). Treatment strategies to restore the functional expression of defective proteins including in vivo and in vitro gene therapy, protein replacement therapy, cell therapy, and pharmacological methods are currently in the clinical trial stage (10).

For mild to moderate esophageal stenosis as a result of common etiology, endoscopic esophageal dilatation is currently the preferred treatment (11). The mucosa of the lesion is removed by endoscopic esophageal stenosis and mucosal peeling, followed by steroid or mitomycin injection into the mucosa. Mycin C is used to reduce the risk of scar re-proliferation. while esophageal stent can also be considered. With time, the fragility of the esophageal mucosa increases, which can be further exacerbated with deteriorating stenosis as a result of esophageal dilation and esophageal stent implantation. At present, there is no effective treatment to halt the further development of esophageal inflammation (12). Our patient had not received any effective treatment for 2 years after the onset of the disease, leading to eventual severe esophageal stricture. Recently, Koklu et al. have described the use of cholecodochoscopy in antegrade-retrograde endoscopy to dilate completely the narrowed esophagus in patients with RDEB-related esophageal stenosis, though the long-term outcome of this procedure remains unclear (13). For severe esophageal stenosis, a gastrostomy may be the ultimate treatment for patients with RDEB (6), given the lack of effective treatment options currently for this genetic disease with progressive severity.

DEB is a rarely seen in the clinic. Through relevant tests and investigations, we have identified ways in which to ameliorate the clinical symptoms, nevertheless there is no effective cure for this type of disease. The means of effecting a complete cure remains a challenge for future investigations.
DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. The patients/participants provided their written informed consent to participate in this study.

REFERENCES

1. Fine J-D, Bruckner-Tuderman L, Eady RAJ, Bauer EA, Bauer JW, Has C, et al. Inherited Epidermolysis Bullosa: Updated Recommendations on Diagnosis and Classification. J Am Acad Dermatol (2014) 70(6):1103–26. Epub 2014 Mar 29. PMID: 24690439. doi:10.1016/j.jaad.2014.01.903
2. Pfendner EG, Lucky AW. Dystrophic Epidermolysis Bullosa. In: MP Adam, HH Ardinger, RA Pagon, SE Wallace, LJH Bean, K Stephens, et al. editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle (2006). updated 2018 Sep 131993–2020. PMID: 20301481.
3. Dang N, Murrell DF. Mutation Analysis and Characterization of COL7A1 Mutations in Dystrophic Epidermolysis Bullosa. Exp Dermatol (2008) 17(7): 553–68. PMID: 18558993. doi:10.1111/j.1600-0625.2008.00723.x
4. Jensen GL, Cederholm T, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, et al. GLIM Criteria for the Diagnosis of Malnutrition: A Consensus Report from the Global Clinical Nutrition Community. JPEN J Parenter Enteral Nutr (2019) 43(1):32–40. Epub 2018 Sep 2. PMID: 30175461. doi:10.1002/jpen.1440
5. Laimer M, Prodinger C, Bauer JW. Hereditary Epidermolysis Bullosa. JDDG: J der Deutschen Dermatologischen Gesellschaft (2015) 13(11):1125–33. PMID: 26513070. doi:10.1111/ddg.12774
6. Tang JY, Marinovich MP, Lucas E, Gorell E, Chio A, Lu Y, et al. A Systematic Literature Review of the Disease burden in Patients with Recessive Dystrophic Epidermolysis Bullosa. Orphanet J Rare Dis (2021) 16(1):175. doi:10.1186/s13023-021-01811-7
7. Inamadar AC. Losartan as Disease Modulating Therapy for Recessive Dystrophic Epidermolysis Bullosa. Dermatol Ther (2020) 33:e14279. Epub ahead of print. PMID: 32888385. doi:10.1111/dth.14279
8. Aguado T, García M, García A, Ferrer-Mayorga G, Martinez-Santamaría L, Del Rio M, et al. Raloxifene and N-Acetylcyesteine Ameliorate TGF-Signalling in Fibroblasts from Patients with Recessive Dominant Epidermolysis Bullosa. Cells (2020) 9(9):E2108. PMID: 32947957. doi:10.3390/cells9092108
9. Bornert O, Hogervorst M, Nauroy P, Bischof J, Swildens J, Athanasiou I, et al. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study. J Invest Dermatol (2021) 141(4):883–93. e6. Epub 2020 Sep 16. PMID: 32946877. doi:10.1016/j.jid.2020.08.018
10. Titeux M, Bonnet des Claustres M, Izmiryan A, Ragot H, Hovnanian A. Emerging Drugs for the Treatment of Epidermolysis Bullosa. Expert Opin Emerging Drugs (2020) 25:467–89. Epub ahead of print. PMID: 33094671. doi:10.1080/14728214.2020.1839049
11. Poincloux L, Rosquette O, Abergel A. Endoscopic Treatment of Benign Esophageal Strictures: a Literature Review. Expert Rev Gastroenterol Hepatol (2017) 11(1):53–64. PMID: 27835929. Epub 2016 Nov 22. doi:10.1080/17474124.2017.1260002
12. Ravich WJ. Endoscopic Management of Benign Esophageal Strictures. Curr Gastroenterol Rep (2017) 19(10):50. PMID: 28840483. doi:10.1007/s11894-017-0591-8
13. Koklu H, Vahabov C, Parlak E, Kav T. Choledochoscope-assisted Antegrade-Retrograde Endoscopic Dilatation of Complete Esophageal Stenosis in a Patient with Dystrophic Epidermolysis Bullosa. Acta Gastroenterol Belg (2020) 83(3): 491–2. PMID: 33094601.

Copyright © 2022 Xu, Huang, Pan, Huang and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

AUTHOR CONTRIBUTIONS

ZX and YJ reviewed and edited the manuscript. ZX and TH completed the manuscript. MP and YH were in charge of literature retrieval. All authors read and approved the final manuscript.

CONFLICT OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.